glp 1 agonists on the market GLP-1 Exclusive Research Report 2025 Market Overview: GLP-1 Agonists and

Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline

Are GLP-1 drugs an 'existential threat' to the food industry or an opportunity to cash in with 'companion' products and 'Nature's Ozempic'?

Across large employers that cover the drugs for weight loss, many require participation in lifestyle or nutrition programs before coverage applies

Cayman offers these agents for research use only to support research in metabolic diseases like T2D and obesity